The study was double-blinded. The investigation drug and placebo had an identical appearance. The study remained blinded to all individuals (including patients, investigators, and study personnel) until the time of prespecified unblinding, except for the statistician who provided the randomization sequence. The randomization list and blinding codes will be kept strictly confidential.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.